Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2014

Hospitalization rates in patients switched from oral
anti-psychotics to aripiprazole once-monthly: final
efficacy analysis
John Kane
Hofstra Northwell School of Medicine

C. Zhao
B. R. Johnson
R. A. Baker
A. Eramo
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Medical Molecular Biology Commons, and the Psychiatry Commons
Recommended Citation
Kane J, Zhao C, Johnson B, Baker R, Eramo A, McQuade R, Duca A, Sanchez R, Peters-Strickland T. Hospitalization rates in patients
switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. . 2014 Jan 01; 18(2):Article 1047 [ p.].
Available from: https://academicworks.medicine.hofstra.edu/articles/1047. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

Authors

John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. McQuade, A. R. Duca, R. Sanchez, and T.
Peters-Strickland

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/1047

Journal of Medical Economics
1369-6998
doi:10.3111/13696998.2014.979936

Vol. 18, No. 2, 2015, 145–154

Article 0095.R1/979936
All rights reserved: reproduction in whole or part not permitted

Original article
Hospitalization rates in patients switched
from oral anti-psychotics to aripiprazole
once-monthly: final efficacy analysis

John M. Kane
The Zucker Hillside Hospital, Glen Oaks, and the
Hofstra North Shore-LIJ School of Medicine,
Hempstead, NY, USA

Cathy Zhao
Biostatistics, Otsuka Pharmaceutical Development &
Commercialization, Inc., Princeton, NJ, USA

Brian R. Johnson
Clinical Management, Otsuka Pharmaceutical
Development & Commercialization, Inc., Princeton,
NJ, USA

Ross A. Baker
CNS Global Medical Affairs, Otsuka Pharmaceutical
Development & Commercialization, Inc., Princeton,
NJ, USA

Anna Eramo
Medical Affairs & Phase IV Clinical Affairs, Lundbeck
LLC, Deerfield, IL, USA

Robert D. McQuade
Global Medical, Regulatory Affairs and Alliances,
Otsuka Pharmaceutical Development &
Commercialization, Inc., Princeton, NJ, USA

Anna R. Duca
Clinical Management, Otsuka Pharmaceutical
Development & Commercialization, Inc., Princeton,
NJ, USA

Raymond Sanchez
Timothy Peters-Strickland
Global Clinical Development (CNS), Otsuka
Pharmaceutical Development & Commercialization,
Inc., Princeton, NJ, USA
Address for correspondence:
John M. Kane, MD, The Zucker Hillside Hospital, 7559 263rd Street, Kaufmann Building, Suite 103, Glen
Oaks, NY 11004-1100, USA.
Tel: 718-470-8141; Fax: 718-343-7739;
jkane2@nshs.edu

! 2015 Informa UK Ltd www.informahealthcare.com/jme

Abstract
Objective:
To compare hospitalization rates in patients with schizophrenia treated prospectively with aripiprazole oncemonthly 400 mg (AOM 400; an extended-release injectable suspension) vs the same patients’ retrospective
rates with their prior oral anti-psychotic therapy.
Research design and methods:
Multi-center, open-label, mirror-image, naturalistic study in a community setting in North America. Patients
who required a change in treatment and/or would benefit from long-acting injectable anti-psychotic therapy
were treated prospectively for 6 months with AOM 400. Retrospective data on hospitalization rates were
obtained.
Clinical trial registration:
ClinicalTrials.gov: NCT01432444.
Main outcome measures:
The proportion of patients with 1 psychiatric inpatient hospitalization with oral anti-psychotic therapy
examined retrospectively (months –4 to –1 before oral conversion) and after switching to AOM 400 (months
4–6 after initiating AOM 400).
Results:
Psychiatric hospitalization rates were significantly lower when patients were treated with AOM 400
compared with oral anti-psychotic therapy both in the 3-month primary efficacy sample (2.7% [n ¼ 9/
336] vs 27.1% [n ¼ 91/336], respectively; p50.0001) and in the total sample (6-month prospective rate:
8.8% [n ¼ 38/433] vs 6-month retrospective rate: 38.1% [n ¼ 165/433]; p50.0001). Discontinuations
due to adverse events (AEs) during cross-titration were lower in patients cross-titrated on oral aripiprazole
for 41 and 54 weeks (2.9% [n ¼ 7/239]) compared with patients cross-titrated for 1 week (10.4%
[n ¼ 5/48]). The most common treatment-emergent AEs during the prospective treatment phase were
insomnia (6.7% [n ¼ 29/431]) and akathisia (6.5% [n ¼ 28/431]). Patient-rated injection-site pain
decreased from the first injection to the last visit.
Conclusions:
In a community setting, patients with schizophrenia demonstrated significantly lower psychiatric
hospitalization rates after switching from their prior oral anti-psychotic therapy to AOM 400. Patients
served as their own control, and thus an active control group was not included in this study.
Confounding factors, such as insurance coverage and availability of hospital beds, were not examined
here and deserve further consideration.
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Introduction
Schizophrenia is estimated to affect 24 million individuals worldwide1. Total
costs related to schizophrenia were estimated at $62.7 billion in the US2, and
the total cost of schizophrenia and other psychotic disorders was estimated at
E93.9 billion in Europe3. Direct and indirect costs may be high because schizophrenia is a chronic, lifelong condition with frequent relapses4. One factor that
contributes to relapse and treatment costs is non-adherence to anti-psychotic
medication5–7. Recent estimates suggest that rates of anti-psychotic nonadherence are as high as 60% early in the course of treatment in patients with
schizophrenia6. Furthermore, non-adherence to anti-psychotic medication is
associated with an increase in the number and risk of hospitalizations5–8.
Recent guidelines for the management of schizophrenia recommend improving
medication adherence as a strategy to reduce hospitalization rates and costs in
patients with schizophrenia4,9. Rates of relapse and hospitalization with longacting injectable anti-psychotic medications are comparable or superior to oral
anti-psychotic agents10–15. Results may vary because of methodologic differences in defining relapse or in study design (i.e., naturalistic vs controlled
studies)13–16. Nonetheless, long-acting injectable anti-psychotics provide an
opportunity to improve medication adherence4,9 and reduce hospitalization
rates relative to treatment with oral formulations of the same compound17,18.
Reducing hospitalization rates and improving medication adherence are
key components for improving functional outcomes in patients with
schizophrenia19.
Aripiprazole once-monthly 400 mg, a long-acting injectable formulation of
the dopamine D2 partial agonist aripiprazole20, is approved for the treatment of
schizophrenia21–23. In two long-term, randomized, double-blind studies, aripiprazole once-monthly 400 mg was well tolerated, delayed time to impending
relapse vs placebo24, and demonstrated non-inferiority vs oral aripiprazole in
reducing the rate of impending relapse10. Moreover, data from a preliminary
analysis of the present mirror-image study demonstrated reduced psychiatric
hospitalization rates in patients with schizophrenia who switched from oral
anti-psychotics to aripiprazole once-monthly 400 mg25. Here, we report the
full study results.

Patients and methods
Patients
Details regarding patient inclusion and exclusion criteria were previously
described25. Briefly, adults aged 18–65 years with a duration of schizophrenia
of 41 year that was consistent with criteria in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), and
who had 7 months of retrospective data were eligible for study inclusion.
Patients with other DSM-IV-TR diagnoses were excluded from the study. To
be considered for study inclusion, patients had to have been treated with oral
anti-psychotic therapy in the 7 months before screening and, in the investigator’s opinion, required a change in treatment for any reason (e.g., poor medication adherence, tolerability issues, lack of efficacy) and potentially benefit from
long-term treatment with a long-acting injectable. Eligible patients had 1
inpatient psychiatric hospitalization 4 years before study screening; patients
had to be managed as outpatients for the 4 weeks before signing an informed
consent form and throughout the screening period25. Patients with a history of
146
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Figure 1. Study design. *Patients who were already receiving oral aripiprazole treatment entered the open-label treatment phase (Phase B) without entering
the oral conversion phase (Phase A).

lack of efficacy or intolerance to aripiprazole treatment
were excluded from enrolling in the study.

Study design
Details regarding study design were previously described25.
Briefly, this was a phase IIIb, multi-center, open-label,
mirror-image, naturalistic study in a North American community setting (NCT01432444). The study sites’ ethics
committees approved the protocol in accordance with
the Declaration of Helsinki. The study consisted of a
screening phase and three treatment phases (Figure 1).
During the screening phase (days 2–28), patient eligibility
was determined. Retrospective psychiatric and nonpsychiatric hospitalization data were obtained for the
7-month time frame before screening. This provided
6 months of hospitalization data and 4 weeks of outpatient
data. Study investigators had the option of tapering off
other anti-psychotic medications during the screening
phase, before the first dose of oral aripiprazole, or crosstitration with oral aripiprazole during the oral conversion
phase (Phase A).
Patients receiving anti-psychotics other than oral aripiprazole and who had no prior history of tolerance to
aripiprazole entered the first phase of prospective
! 2015 Informa UK Ltd www.informahealthcare.com/jme

treatment, Phase A. However, those who were already
being treated with oral aripiprazole at the time of study
enrollment or who had a history of tolerating oral aripiprazole could directly enter the 6-month open-label
treatment phase (Phase B) if the study investigator
deemed the patients’ safety would be maintained.
During Phase A (1–4 weeks), patients cross-titrated to
oral aripiprazole (10–30 mg). The recommended starting
dose for oral aripiprazole was 10 or 15 mg/day, depending
on the patient’s symptoms and the investigator’s opinion. The investigators were permitted to titrate the dose
up to 30 mg/day based on their clinical judgment.
Patients who completed Phase A, and those who in
the opinion of the investigator did not require crosstitration to oral aripiprazole, entered Phase B. During
Phase B, patients were treated with aripiprazole oncemonthly 400 mg by intramuscular injection in the gluteal muscle. A dose reduction to 300 mg was permitted if
patients experienced tolerability issues. For the first 14
days of Phase B, patients received concomitant oral aripiprazole (10–20 mg) following their initial dose
of aripiprazole once-monthly 400 mg. During these first
14 days, patients received oral aripiprazole 10 mg/day
unless they were currently receiving oral aripiprazole
420–30 mg/day, in which case they received oral
Hospitalization rates when switched to aripiprazole once-monthly Kane et al.
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aripiprazole 15 mg/day for the first 14 days of treatment
in Phase B. The initial doses for the first 14 days of
aripiprazole once-monthly 400 mg treatment were treatment recommendations—study investigators had the
option to increase the dose for efficacy to a maximum
of 20 mg/day or decrease the dose for tolerability to a
minimum of 10 mg/day; changes to the oral aripiprazole
daily dose during the first 14 days of Phase B were made
in 5-mg increments.
Patients were assessed at baseline (week 0), week 1,
week 2, week 4, and every 4 weeks thereafter up to
24 weeks. Patients who completed Phase B and who, in
the opinion of the investigator, would benefit from continued therapy with aripiprazole once-monthly were eligible to continue treatment in an extension phase. During
the extension phase, patients continued to receive aripiprazole once-monthly at 400 or 300 mg. Data from the
extension phase will be reported separately as it is not
part of the primary analysis.

End-points
The primary end-point was the total psychiatric hospitalization rate, defined as the proportion of patients with 1
psychiatric hospitalization. Rates were compared between
the retrospective oral anti-psychotic treatment period
(months –4 to –1 before screening) and during prospective
aripiprazole once-monthly therapy (months 4–6, the last
3 months of Phase B) in patients who entered Phase B and
completed 3 months of treatment (3-month primary efficacy sample).
Secondary efficacy end-points included the 6-month
hospitalization rate during prospective aripiprazole oncemonthly therapy (months 1–6) compared with the
6-month retrospective period (months –7 to –1) among
all patients who entered Phase B (total efficacy sample);
the cumulative and mean durations of inpatient psychiatric hospitalizations for months –4 to –1 and months 4 to
6; the number of psychiatric emergency room visits during
months –4 to –1 and months 4 to 6; and the number,
cumulative duration, and mean duration of the following
end-points for months –4 to –1 and months 4 to 6: inpatient hospitalizations for psychosocial reasons, psychiatric
partial hospitalizations, and psychiatric intensive outpatient programs.
Safety and tolerability end-points included adverse
events (AEs), clinical laboratory tests, vital signs, electrocardiograms, physical examinations, weight, height, body
mass index, extrapyramidal symptoms, investigator ratings
of injection-site reactions, and patient ratings of injectionsite pain using a visual analog scale. Suicidality was
assessed using the Columbia Suicide Severity Rating
Scale (C-SSRS).
148
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Data analytic procedures and statistical analysis
Data analytic procedures and statistical analyses were previously described25. Briefly, total psychiatric hospitalization rates were calculated for patients who entered Phase
B and completed 3 months of treatment. Comparisons
between rates during the retrospective oral anti-psychotic
treatment period (months –4 to –1) and the prospective
aripiprazole once-monthly treatment period (months 4–6)
were assessed using exact McNemar’s tests with statistical
significance at an alpha level of 0.05 (two-sided). Sample
size was estimated at 230 to provide 99% power to detect
a statistically significant difference of 15% in two paired
hospitalization proportions between pre-switch and postswitch periods, while the proportion of total discordant
pairs was 25%; this was based on the assumption that
30% of patients would be hospitalized pre-switch and,
overall, 15% would be hospitalized post-switch (10%
would be hospitalized both pre-switch and post-switch
and 5% with no pre-switch hospitalization). McNemar’s
test was conducted on the difference in the discordant
rates of total psychiatric hospitalizations, defined as the
proportion of patients with 1 psychiatric hospitalization
in the prospective treatment period and 0 hospitalizations
in the retrospective period, minus the proportion of
patients with 0 hospitalizations in the prospective treatment period and 1 hospitalization in the retrospective
period. New and ongoing hospitalizations that occurred
during the 3-month periods were included in the analyses.
Paired t-tests were also conducted, when applicable, for the
number of hospitalization stays per subject, cumulative
duration of hospitalization, mean duration of hospitalization, and the number and mean duration of all other outpatient hospitalization programs during the retrospective
(months –4 to –1) vs prospective (months 4–6) treatment
periods for patients with 3 months of aripiprazole oncemonthly treatment during Phase B. The rate ratio was
calculated from the rates before and after switching to
aripiprazole once-monthly treatment.
A sensitivity analysis was also conducted to assess the
potential impact of discontinuation on total psychiatric
hospitalization rates. Missing data were imputed for total
psychiatric hospitalization rates between the 6-month
retrospective and prospective Phase B periods for all
patients who received aripiprazole once-monthly treatment. For the sensitivity analysis, patients who discontinued aripiprazole once-monthly during Phase B for
psychiatric AEs (excluding insomnia) or lack of efficacy
were treated as having one imputed psychiatric hospitalization during the 6-month prospective period. Moreover,
to examine the effect of duration of cross-titration, the rate
of discontinuations due to AEs in Phase A was analyzed in
a post-hoc analysis, stratified by duration of oral aripiprazole cross-titration period (1 week vs41 and 4 weeks).
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Patients not requiring
cross-titration entered
Phase B directly (n=168)

Screening

Phase A
Oral conversion

Days 2–28

1–4 weeks

n=800

n=325

Failed screening: 307
Did not meet inclusion criteria: 76 (24.8%)
Met exclusion criteria: 123 (40.1%)
Withdrew consent: 44 (14.3%)
Withdrawn by investigator: 14 (4.6%)
Other: 50 (16.3%)

Discontinued: 60 (18.5%)
Withdrew consent: 15 (4.6%)
AEs: 16 (4.9%)
Lost to follow-up: 10 (3.1%)
Lack of efficacy: 5 (1.5%)
Other*: 14 (4.3%)

Phase B
Open-label treatment
6 months
n=433

Discontinued: 140 (32.3%)
Withdrew consent: 41 (9.5%)
AEs: 37 (8.5%)
Lost to follow-up: 33 (7.6%)
Lack of efficacy: 10 (2.3%)
Other*: 19 (4.4%)

Figure 2. Patient disposition during the prospective period. *Patients met withdrawal criteria, were withdrawn by the study investigator, or had a protocol
deviation. AE ¼ adverse event.

Results
Patients
Of 800 patients screened, 493 were eligible for study
inclusion and enrolled in the study. A total of 325 patients
entered the study in Phase A (Figure 2), the oral conversion phase, and 168 patients did not require cross-titration
to oral aripiprazole based on their history with oral
aripiprazole therapy and the investigator’s opinion, and
thus entered the study in Phase B, the 6-month openlabel treatment period with aripiprazole once-monthly.
Sixty patients discontinued during Phase A (Figure 2);
the primary reasons were AEs (4.9%) and withdrawn
consent to participate (4.6%). There were 433 patients
in Phase B (intent-to-treat population), 431 of whom
received at least one aripiprazole once-monthly injection
(Phase B safety population). 336 patients entered the
fourth month of Phase B and were part of the primary
efficacy analysis, and 293 completed treatment. There
were 140 patients who discontinued during Phase B; primary reasons for discontinuation were withdrawn consent
to participate (9.5%) and AEs (8.5%). Of those patients
who completed Phase B, there were 192 patients who,
in the opinion of the investigator, would benefit from
continued aripiprazole once-monthly therapy and, thus,
continued treatment in the extension phase (results not
shown).
! 2015 Informa UK Ltd www.informahealthcare.com/jme

Ninety-nine per cent (290/293) of patients who completed Phase B initiated treatment on aripiprazole oncemonthly at 400 mg; three patients initiated aripiprazole
once-monthly therapy at 300 mg. Most patients (240/293
[82%]) who completed Phase B started and remained on
the 400-mg dose of aripiprazole once-monthly throughout
Phase B. At the last (6th) injection, 86% of patients
received aripiprazole once-monthly 400 mg, and the
remainder received 300 mg. Thirteen per cent of patients
(n ¼ 39/293) who completed Phase B had their dose
decreased from 400 to 300 mg, and 4% (n ¼ 11/293) had
their dose decreased from 400 to 300 mg and then
increased thereafter to 400 mg. Three patients started on
aripiprazole once-monthly 300 mg, which were protocol
deviations; two of these patients remained on aripiprazole
once-monthly 300 mg, and one patient had a dose increase
to 400 mg.
Baseline demographic and disease characteristics by
study phase for patients who entered each respective
phase are reported in Table 1. The majority of the patients
were male (n ¼ 301/433, 70%), half (n ¼ 216/433) were
white, and 46% (n ¼ 198/433) were black. Disease severity
at Phase B baseline was moderate (Clinical Global
Impression-Severity of Illness scale, 3.7  0.8); common
concomitant central nervous system medications taken
during Phase B included psycholeptics (including aripiprazole) in 206 patients (47.6%), psycho-analeptics in
169 patients (39.0%), and anti-parkinsonian medications
in 103 patients (23.8%).
Hospitalization rates when switched to aripiprazole once-monthly Kane et al.
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Total psychiatric hospitalization rates
Inpatient psychiatric hospitalization rates in patients
who were treated with aripiprazole once-monthly for
3 months were significantly lower during prospective
Table 1. Demographics and baseline characteristics by study phase.

Age, mean (SD), years
Men/women, n
Body weight, mean (SD), kg*
BMI, mean (SD), kg/m2*
Race, n (%)
White
Black
American Indian or Alaska Native
Asian
Other
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
PANSS total score, mean (SD)y
Conceptual disorganization (P2)
Suspiciousness (P6)
Hallucinatory (P3)
Unusual thought content (G9)
CGI severity score, mean (SD)z
Age at first diagnosis, mean (SD), yearsx

Phase A
(n ¼ 325)

Phase B
(n ¼ 433)

42.7 (11.9)
239/86
90.6 (20.9)
30.4 (6.9)

42.1 (12.0)
301/132
91.2 (21.2)
30.8 (7.1)

150 (46.2)
159 (48.9)
2 (0.6)
8 (2.5)
6 (1.8)

216 (49.9)
198 (45.7)
3 (0.7)
10 (2.3)
6 (1.4)

77 (23.7)
248 (76.3)
N/A

94 (21.7)
339 (78.3)
75.0 (18.3)
2.8 (1.2)
3.2 (1.1)
3.0 (1.4)
2.6 (1.1)
3.7 (0.8)
26.7 (10.5)

N/A
26.8 (10.7)

Patients With ≥1 Psychiatric Hospitalization, %

BMI, body mass index; CGI, Clinical Global Impressions; N/A, not available;
PANSS, Positive and Negative Syndrome Scale.
*n ¼ 312 (Phase A), n ¼ 422 (Phase B).
yn ¼ 427 (Phase B).
zn ¼ 425 (Phase B).
xn ¼ 318 (Phase A), n ¼ 427 (Phase B).
Data represent all patients who enrolled in each study phase.

months 4–6, when patients were treated with aripiprazole
once-monthly at 400 mg, compared with their retrospective rates during months –4 to –1, when treated with oral
anti-psychotic therapy (2.7% [n ¼ 9/336] vs 27.1%
[n ¼ 91/336], respectively; p50.0001; Figure 3). Rates
were also significantly lower for all Phase B patients
during the 6-month prospective period vs their rates
during the 6-month retrospective period (8.8% [n ¼ 38/
433] vs 38.1% [n ¼ 165/433], p50.0001; Figure 3). The
rate ratios for hospitalization during the prospective vs
retrospective periods were 0.10 for patients who completed
3 months of treatment on aripiprazole once-monthly and
0.23 for all patients who entered Phase B.
The sensitivity analysis included data for 55 patients
with observed or imputed (based on study discontinuation)
psychiatric inpatient hospitalizations during the prospective period. This analysis also demonstrated significant
reductions in total psychiatric hospitalizations during
months 1–6 of prospective treatment with aripiprazole
once-monthly compared with retrospective treatment
during months –7 to –1 with oral anti-psychotic therapy
(12.7% [n ¼ 55/433] vs 38.1% [n ¼ 165/433], respectively,
p50.0001).

Other secondary efficacy end-points
A breakdown of hospital resource use is provided in
Table 2. The data are summarized for patients having
the event during the retrospective (months –4 to –1)
and prospective (months 4–6) periods. Mean cumulative
duration of inpatient psychiatric hospitalizations per
patient was reduced by 4 days in the prospective

50
45

Retrospective

Prospective
38.1

40
35
30

27.1

25
20
15

*
8.8

10
*
2.7

5
0

Months
−4 to −1

Months
4 to 6

3-Month Primary Efficacy Sample (n=336)
*P<0.0001

Months
−7 to −1

Months
1 to 6

Total Sample (n=433)

Figure 3. Total psychiatric hospitalization rates following the switch to aripiprazole once-monthly 400 mg (prospective) compared with the same patients
treated with oral antipsychotics (retrospective). P value derived from exact McNemar test. AOM 400 ¼ aripiprazole once-monthly 400 mg.

150

Hospitalization rates when switched to aripiprazole once-monthly Kane et al.

www.informahealthcare.com/jme ! 2015 Informa UK Ltd

Journal of Medical Economics

Volume 18, Number 2

February 2015

Table 2. Hospitalization data.

Inpatient psychiatric hospitalizations
Total number of events/patients with event
Mean cumulative duration (range), days
Inpatient hospitalizations for psychosocial reasons
Total number of events/patients with event
Mean number of events per patient (range)
Mean cumulative duration (range), days
Psychiatric partial hospitalizations
Total number of events/patients with event
Mean number of events per patient (range)
Mean cumulative duration (range), days
Psychiatric intensive outpatient programs
Total number of events/patients with event
Mean number of events per patient (range)
Psychiatric ER visits
Total number of events/patients with event
Mean number of events per patient (range)

Retrospective
months –4 to –1
(n ¼ 336)

Prospective
months 4–6
(n ¼ 336)

104/91
11.1 (2–57)

10/9
7.0 (2–16)

7/7
1.0 (1–1)
15.6 (4–31)

0/0
–
–

2/2
1 (1–1)
5.9 (0.4–11.4)
4/4
1 (1–1)
34/23
1.5 (1–5)

0/0
–
–
0/0
–
4/4
1 (1–1)

ER, emergency room; n, number of patients.

aripiprazole once-monthly 400 mg treatment period
(7.0 days) vs the retrospective period (11.1 days;
Table 2). No patient was hospitalized for psychosocial reasons or participated in psychiatric intensive outpatient or
partial inpatient programs during the prospective period.
In contrast, seven patients were hospitalized once for psychosocial reasons, with a mean cumulative duration of
15.6 days, four patients participated in psychiatric intensive outpatient programs, and two patients participated in
psychiatric partial inpatient programs in the retrospective
period. Likewise, the number of psychiatric emergency
room visits and the mean number of visits per patient
were both lower in the prospective period compared with
the retrospective period.

Safety
Of the 433 patients who entered Phase B, 431 received 1
dose of aripiprazole once-monthly and were thus included
in the safety analysis. The incidence of treatment-emergent AEs (TEAEs) during Phase B that occurred in 2% of
patients is reported in Table 3. Sixty-one per cent of
patients (n ¼ 265/431) experienced a TEAE. Many
TEAEs occurred 51 month after treatment initiation
(n ¼ 162/431 [37.6%]), and the incidence decreased each
month thereafter (months 1–2: n ¼ 79/420 [18.8%],
months 2–3: n ¼ 66/397 [16.6%], months 3–4: n ¼ 57/
364 [15.7%], months 4–5: n ¼ 35/342 [10.2%], months
5–6: n ¼ 35/317 [11.0%], 46 months: 2/298 [0.7%]).
Most TEAEs were mild or moderate in severity during
Phase B. There were 42 (9.7%) patients who had a
severe TEAE during Phase B; the most common severe
TEAEs were psychotic disorder (7/431 [1.6%]) and schizophrenia (5/431 [1.2%]).
! 2015 Informa UK Ltd www.informahealthcare.com/jme

Table 3. Incidence of treatment-emergent adverse events occurring in
2% of all patients treated in phase B (n ¼ 431).
Adverse event
Insomnia
Akathisia
Psychotic disorder
Schizophrenia
Injection-site pain
Anxiety
Back pain
Headache
Schizophrenia, paranoid type
Hallucination, auditory
Tremor
Sedation
Nausea
Depression
Diarrhea
Somnolence
Suicidal ideation
Weight increased
Dizziness
Toothache

n (%)
29 (6.7)
28 (6.5)
21 (4.9)
20 (4.6)
19 (4.4)
17 (3.9)
15 (3.5)
14 (3.2)
14 (3.2)
13 (3.0)
13 (3.0)
12 (2.8)
11 (2.6)
10 (2.3)
10 (2.3)
10 (2.3)
10 (2.3)
10 (2.3)
9 (2.1)
9 (2.1)

Data represent patients from the Phase B safety population, patients receiving 1 dose of study medication in the corresponding study phase.
Treatment-emergent adverse events were defined as adverse events that
occurred after the start of study drug treatment, or if the event was continuous from baseline and was serious, study drug related, or resulted in
death, discontinuation, interruption, or reduction of study therapy.

Discontinuation rates due to AEs varied with duration of cross-titration in Phase A before initiating aripiprazole once-monthly at 400 mg. Among those who
cross-titrated to oral aripiprazole for 1 week, 10.4%
(n ¼ 5/48) discontinued during Phase A because of
AEs, whereas 2.9% (n ¼ 7/239) of patients who crosstitrated to oral aripiprazole for 41 and 4 weeks discontinued because of AEs.
Hospitalization rates when switched to aripiprazole once-monthly Kane et al.
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Table 4. Incidence of potentially clinically relevant treatment-emergent
changes in lipids, prolactin levels, and weight in phase B (n ¼ 431).
Parameter

Total fasting cholesterol 240 mg/dL
Fasting LDL cholesterol 160 mg/dL
Fasting HDL cholesterol 30 mg/dL
Fasting triglycerides 120 mg/dL
(women) or 160 mg/dL (men)
Fasting glucose 115 mg/dL
Prolactin level 41  ULN
Weight gain 7%
Weight loss 7%

Number
examined*

ny(%)

350
344
350
350

46 (13.1)
35 (10.2)
12 (3.4)
134 (38.3)

350
375
359
359

70 (20.0)
15 (4.0)
22 (6.1)
25 (7.0)

HDL, high-density lipoprotein; LDL, low-density lipoprotein; ULN, upper limit
of normal.
*Total number of patients with baseline value and 1 post-baseline value in
Phase B.
yn ¼ number of patients with a potentially clinically relevant change; the
denominator for percentage calculation is number examined.

The incidence of potentially clinically relevant changes
in lipid parameters, prolactin level, and weight in Phase B
are listed in Table 4. Although some patients experienced
weight gain 7% (n ¼ 22 [6.1%]) or weight loss 7%
(n ¼ 25 [7.0%]), and 10 patients (2.3%) reported weight
increased as an AE during phase B, there were no clinically
relevant mean changes from baseline in weight and other
vital signs (including blood pressure and heart rate).
Mean  SD weight change from Phase B baseline to last
visit was minimal (–0.2  3.9 kg) and similar between
black (0.3  4.0 kg, n ¼ 165) and non-black patients
(0.1  3.9 kg, n ¼ 194). There were no clinically relevant mean changes from baseline in laboratory values,
electrocardiogram parameters, extrapyramidal symptoms,
or suicidality during phase B. Mean  SD C-SSRS suicidal
ideation total scores remained stable from Phase B baseline
(0.1  1.1) to last visit (0.4  2.1). Patient-rated injectionsite pain decreased from Phase B baseline (7.2  13.4) to
Phase B last visit (5.6  11.4). Physicians rated the majority of their patients’ injection-site pain as absent at all
assessments during Phase B.

Discussion
Results of the present final analysis confirm the findings
from the preliminary analysis demonstrating a reduction in
the number of psychiatric hospitalizations after switching
to aripiprazole once-monthly at 400 mg vs prior treatment
with oral anti-psychotics before study enrollment25. The
significant improvement in other secondary outcomes
(e.g., per-patient psychiatric emergency room visits,
mean length of hospitalization) in the prospective vs the
retrospective period further supports the effectiveness and
potential for cost savings when using aripiprazole oncemonthly at 400 mg in a community setting in patients
152
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switching from oral anti-psychotic therapy. The AE profile
was comparable to prospective, randomized controlled
trials of aripiprazole once-monthly at 400 mg as maintenance treatment in patients with schizophrenia10,24 and as
treatment of acute exacerbations of psychotic symptoms in
patients with schizophrenia26. Furthermore, the lower rate
of discontinuation due to AEs in patients who crosstitrated to oral aripiprazole for 41 and 4 weeks vs those
whose length of cross-titration was 1 week in Phase A
suggests that a 41- to 4-week length of cross-titration is
preferable.
The findings on the effectiveness of aripiprazole oncemonthly at 400 mg are also consistent with other clinical
studies and analyses of claims databases demonstrating
reduced psychiatric hospitalizations with long-acting
injectable anti-psychotics relative to oral anti-psychotic
therapy18,27–30. In a meta-analysis, 15 of 16 mirror-image
studies showed that long-acting injectable anti-psychotics
reduced the risk of hospitalization relative to oral antipsychotics15. Another meta-analysis of 13 studies showed
that research design affects the assessment of comparative
effectiveness (e.g., hospitalization rates), with observational studies being more sensitive to differences than randomized controlled trials where adherence is fostered
through regular study visits16.
Fewer psychiatric hospitalizations may also contribute
to substantial cost savings with long-acting injectable antipsychotic therapy27,29,31,32. For example, in another
mirror-image study using a US commercial claims database, patients with schizophrenia who initiated depot
anti-psychotic medication had lower all-cause and schizophrenia-related inpatient costs relative to their pre-initiation index period, although outpatient costs remained
comparable31. In addition to reduced total hospitalizations, the present results showed that the average duration
of psychiatric inpatient hospitalization was 4 days shorter
after patients switched to aripiprazole once-monthly.
Other potential indirect cost benefits with the use of
long-acting injectable anti-psychotics may derive from
fewer disruptions in work and family/social functioning
due to fewer relapses and hospitalizations. Some health
insurance providers may limit access to or reimbursement
for long-acting injectable anti-psychotic therapy to minimize prescription costs33. However, the potential direct
and indirect cost savings through reduced psychiatric hospitalizations, per-patient psychiatric emergency room
visits, mean length of hospitalization, and hospitalizations
for psychosocial reasons may offset prescription costs.
Safety and tolerability after initiation of aripiprazole
once-monthly at 400 mg were consistent with previous
experience with aripiprazole tablets34. Patients may benefit from active management of more common AEs such as
insomnia and akathisia. Minimal mean weight change was
observed in the current study (0.2  3.9 kg), and notably,
black patients showed no mean weight gain. The lack of
www.informahealthcare.com/jme ! 2015 Informa UK Ltd
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weight gain among black patients may relate to the fact
that all patients were relatively stable upon study entry,
and few were hospitalized during the prospective period.
A previous study of aripiprazole once-monthly at 400 mg
for the treatment of acute exacerbations of psychotic
symptoms found significant weight gain correlated with
time in hospital26. Minimal weight change during outpatient maintenance treatment is consistent with other
maintenance studies with aripiprazole once-monthly at
400 mg10,24. The favorable metabolic profile of aripiprazole relative to other atypical anti-psychotics may partially
explain its continued use despite availability of generic
atypical anti-psychoticss, risperidone in particular35.
Regardless, all patients treated with any atypical antipsychotic therapy should be regularly monitored for
changes in metabolic parameters36.
Limitations of the current study include lack of an
active control group and non-blinded treatment, both
of which limit the ability to assess the impact of the
study design and study participation on outcomes25.
Confounding factors such as insurance coverage, hospital
bed availability, and physician willingness to hospitalize
patients were not examined in the current analyses25.

Conclusions
In a community setting, patients with schizophrenia
demonstrated significantly lower rates of psychiatric hospitalization after switching to aripiprazole once-monthly
400 mg compared with their rates from retrospective data
during prior oral anti-psychotic therapy. Results are consistent with findings from a preliminary analysis and demonstrate the potential for cost savings when switching
patients from oral anti-psychotic therapy to aripiprazole
once-monthly at 400 mg.
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